Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): November 7, 2011
 
 
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
         
Florida
  
001-33357
  
65-0643773
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
     
2 Snunit Street
  
20100
Science Park, POB 455
    
Carmiel, Israel
    
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code +972-4-988-9488
 
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders
 
The 2011 Annual Meeting of Shareholders of Protalix BioTherapeutics, Inc. (the “Company”) was held on November 7, 2011.  At the meeting:
 
 
(1)
eight persons were elected to serve as directors of the Company;
 
 
(2)
the shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers;
 
 
(3)
the shareholders approved, on a non-binding advisory basis, the frequency of holding future advisory votes on the compensation of the Company’s named executive officers; and
 
 
(4)
the shareholders ratified the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), A member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011.
 
Set forth below, with respect to each such matter, are the number of votes cast for, number of votes cast against or withheld, as applicable, the number of abstentions, the number of broker non-votes and other applicable votes.
 
(1) 
Election of Directors
 
   
For
    
Withheld
  
Zeev Bronfeld
     38,614,547       2,748,875  
David Aviezer, Ph.D., MBA
     40,347,781       75,856  
Yoseph Shaaltiel, Ph.D.
     41,287,982       75,536  
Alfred Akirov
     40,938,394       76,597  
Amos Bar Shalev
     40,938,364       76,627  
Yodfat Harel Gross
     41,286,845       76,557  
Roger D. Kornberg, Ph.D.
     41,288,566       74,856  
Eyal Sheratzky
     40,928,835       86,156  

(2) 
Advisory vote on executive compensation

For
  
Against
  
Abstain
  
Broker Nonvotes
35,934,105
  
1,390,374
  
13,261,454
  
10,134,468
 
 
2
 

(3)
Advisory vote on the frequency of holding future advisory votes the compensation of the Company’s named executive officers

1 Year
  
2 Years
  
3 Years
  
Abstain
  
Broker Nonvotes
30,812,378
  
589,212
  
5,865,939
  
3,192,936
  
10,134,468

Based on these results, the Company has decided to hold an advisory vote on the compensation of the Company’s named executive officers every year, until the next required vote on the frequency of the shareholder vote on the compensation of named executive officers.

(4) 
Ratification of appointment of Kesselman & Kesselman

For
  
Against
  
Abstain
49,420,086
  
55,730
  
1,119,117
 
 
3
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  PROTALIX BIOTHERAPEUTICS, INC.  
       
Date: November 8, 2011
By:
/s/ David Aviezer  
  Name: David Aviezer, Ph.D.  
  Title:
President and Chief Executive Officer
  
 
 
4